BTK and B-cell chronic lymphocytic leukemia: In contrast, 90% or more of CLL patients treated with Ibrutinib and Acalabrutinib develop mutations in BTK C481 (Figure 1d, Supplementary file 1, Maddocks et al., 2015; Ahn et al., 2017; Woyach et al., 2014).